Clinical trials are research studies that have been carefully designed to answer questions about new ways to prevent cancer, treat cancer, manage side effects of treatment, and improve quality of life.
The Hall-Perrine Cancer Center participates in national clinical trials through the National Cancer Institute (NCI) and national and international studies through the pharmaceutical industry. These types of clinical trials are leading to major breakthroughs in cancer treatment in our own community.
Through the Iowa-Wide Oncology Research Coalition (I-WORC), Oncology Associates at Mercy Medical Center actively participates in more than 40 clinical trials at any given time. This allows a great number of patients access to trials based on the cancer and stage of cancer.
or Kelli Mitchell at (319) 363-2690 ext. 2 or kmitchell@mercycare.org
Brain
Breast
A011202:
Rand Ph III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Br Ca Pts (CT1-3N1) who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
NRG-BR003:
Rand Ph III Trial of Adjuvant Therapy Comparing Doxorubicin + Cyclophosphamide Followed by Weekly Paclitaxel w/ or w/o Carboplatin for Node-Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer
NRG-BR004:
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502
EA1181: (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
A191901: Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Gastrointestinal
S0820: Double-Blind Placebo-Controlled Trial of Eflornithine & Sulindac to Prevent Recurrence of High Risk Adenomas & Second Primary Colorectal Cancers in Pts w/ Stage 0-III Colon or Rectal Ca, Ph III- Preventing Adenomas of the Colon w/ Eflornithine & Sulindac (PACES)
A021502: Randomized Trial of Standard Chemotherapy Alone or
Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III
Colon Cancer and Deficient DNA Mismatch Repair
WF-1806:Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
NRG-GI004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
A021703: Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A
Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
NRG-GI005: Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Genitourinary
NRG-GU002 - PhaseII-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following
Radical Prostatectomy with or Without Adjuvant Docetaxel
Gynecological
NRG RTOG-0724:
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Head and Neck
Hematologic
NHLBI-MDS:
The National Myelodysplastic Syndromes (MDS) Study
S1826:
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
EAA181: Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
Lung
A151216:
Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial (ALCHEMIST) **Screening trial for A081105 and E4512**
A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO - **Must be enrolled on screening trial A151216**
E4512:
Ph III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib Vs. Placebo for Pts w/ Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein **Must be enrolled on screening trial A151216**
EA5163: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker
SIGNature-Driven Analysis
LUNGMAP:
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
S1900E: A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
NRG-LU005:
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Skin/Melanoma
S1801:
Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475
(Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
EA6174: STAMP: Surgically
Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial
Other
DCP-001:
Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
S1609:
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
NCI 10323: Cancer Moonshot Biobank Research Protocol
S1714: Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients – This is for Breast, Ovarian and NSCLC cancers
A021602: Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with
Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Symptom Management/Cancer Control
A221602: Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC):
A Phase III Randomized, Double Blind, Placebo-Controlled Trial
WF-1804CD: Automated Heart-Health Assessment for Cancer Survivors – Assessing Effectiveness and Implementation of an HER Tool to Assess Heart Health among Survivors ( AH-HA)
S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Thyroid
